reported a 4% year-on-year increase in net profit to ₹255.3 crore for the first quarter ending June 30, 2025. Revenue rose 13.8% to ₹1,302.7 crore, and EBITDA grew 6.3% to ₹351.3 crore. The company's India branded generics business outpaced IPM growth by 29% in Q1 FY26. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

#Miscellaneous

656 likes·83 comments